Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • swhitemd50 swhitemd50 Nov 9, 2011 8:30 AM Flag

    Tomorrow’s Credit Suisse CC

    Hopefully, Vertex will have a better response to questions of future competition from other hep C drug developers. Ian Smith, the CFO, still has 27,793 shares of VRTX so he should have done a better job at the November 8 conference. Sounds like he was praising Pharmasset. In any case, the CFO is probably the worst choice to explain complicated scientific matters regarding hep C drugs in development. I think it is time for Peter Mueller, Vertex's chief scientific officer, to step up and make the case for why Vertex will remain the leader in the treatment of hep C in the short term and the long term.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
VRTX
131.26+5.07(+4.02%)Jul 2 4:00 PMEDT